Pancreatic Cancer Initial Detection Via Liquid Biopsy

Condition(s) studied

Investigational drug(s) / intervention(s)

Liquid biopsy: Blood will be drawn upon clinical diagnosis / prior to biopsy/surgical resection for "ground truth"

Study summary

The overall rationale of PANCAID is to provide a diagnostic blood test for early diagnosis of pancreatic cancer. With a set of different liquid biopsy methods, it is the aim to measure these markers in well-defined patient cohorts. For the entire series of these studies, the following groups are planned: 1) Histologically proven early-stage pancreatic cancer (e.g. T1a/b and T2 carcinomas \[N0M0\]); 2) Intraductal papillary mucinous neoplasia (IPMN) that were operated with verification of the benign, premalignant or malignant histology; 3) ordinary branched-duct IPMN; 4) individuals at risk (IAR) with and without IPMN, with and without known hereditary cancer gene (e.g. BRCA2); 5) a high risk group of patients with chronic pancreatitis, aged 55-65, who are heavy smokers (≥40 PY), with newly onset diabetes mellitus (NODM).

Eligibility

Primary outcome measure(s)

• Cancer detection — Up to 4 weeks after surgery
  Liquid biopsy test(s) detecting pancreatic cancer on biobanked, archival samples of patients with histologically confirmed pancreatic lesions (PDAC, IPMN, pancreatitis).

Trial sites (1)

More Karolinska University Hospital trials in Sweden

Other trials for the same condition